Glutamatergic system dysfunction in schizophrenia. A proton magnetic resonance spectroscopy (1H MRS) study

Polish Journal of Radiology

Volumn 69, Issue 1, 2004, Pages 33-36

  Szulc, Agata ^a   Galińska, Beata ^a   Tarasów, Eugeniusz ^a   Kubas, Bozena ^a   Dzienis, Wojciech ^a   Walecki, Jerzy ^a   Czernikiewicz, Andrzej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glutamatergic system; Proton magnetic resonance spectroscopy; Schizophrenia

Indexed keywords

EID: 63749123861     PISSN: 1733134X     EISSN: 18990967     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kuliszkiewicz-Janus M: Spektroskopia magnetycznego rezonansu jadrowego (Magnetic Resonance Spectroscopy - MRS) w badaniu fizjologii i patologii mózgu. Post Med Klin Dośw, 1993; 2: 167-177.
2. Bertolino A, Weinberger DR: Proton magnetic resonance spectroscopy in schizophrenia. Eur J Radiol, 1999; 30: 132-141.
3. Galińska B, Szulc A, Walecki J et al: Postepy w neuroobrazowaniu schizofrenii: spektroskopia rezonansu magnetycznego, Pol Merk Lek, 2003; XV(87): 279-280.
4. Kegeles LS, Humaran TJ, Mann JJ: In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry, 1998; 44: 382-398.
5. Urbanik A, Sobiecka B, Kozub J et al: Widmo badania RM mózgowia w technice spektroskopii protonowej metoda pojedynczego, zlokalizowanego voxela. Pol Przegl Rad, 2001; 66(l): 7-11.
6. Egan MF, Hyde TM: Schizophrenia: Neurobiology. In: Comprehensive texbook of psychiatry. Kaplan HI, Sadock BJ (eds.) Lippincott Williams & Wilkins, 2000, pp.1129-1144.
7. Choe B, Suh T, Shinn K et al: Obsevation of Metabolic Changes in Chronic Schizophrenia After Neuroleptic Treatment by In Vivo Hydrogen Magnetic Resonance Spectroscopy. Investigative Radiology, 1996; 31(6): 345-352.
8. Stanley JA, Williamson PC, Drost DJ et al: An In Vivo Proton Magnetic Resonance Spectroscopy Study of Schizophrenia Patients. Schizophrenia Bull, 1996; 22: 597-609.
9. Bartha P, Williamson PC, Drost DJ et al: Measurement of Glutamate and Glutamine in the Medial Prefrontal Cortex of Never-Mreated Schizophrenic Patients and Healthy Controls by Proton Magnetic Resonance Spectroscopy. Arch Gen Psychiatry, 1997; 54: 959-965.
10. Theberge J, Bartha R, Drost DJ et al: Glutamate and Glutamine Measured Wlth 4.0 T Proton MRS in Never-Treated Patients With Schizophrenia and Healthy Volunteers. Am J Psychiatry, 2002: 159: 1944-1946.
11. Goff DC, Hermen J, Lyoo IK et al: Modulation of Brain and serum Glutamatergic concentrations Following a switch from Conventional Neuroleptics to Olanzapine. Biol Ptychiatry, 2002; 51: 493-497.
12. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrom Scale (PANSS) for Schizophrenia. Schizophr Bull, 1987; 13: 261-276.
13. Addington D, Addington J, Maticka-Tyndale E: The Calgary Depression Scale. Br J Psychiatry, 1992: 163, suppl. 22: 39-44.
14. Deicken RF, Zhou L, Schuff N et al: Hippocampal Neuronal Dysfunction in Schizophrenia as Measured by Proton Magnetic Resonance Spectroscopy. Biol Psychiatry, 1998; 43: 483-488.
15. Lindquist DM, Hawk RM, Karson CR et al: Effects of Antipsychotic Drugs on Metabolite Ratios i Rat. Brain in Vivo. Magnetic Resonance in Medicine, 2000; 43: 355-358.
16. Bertolino A, Callicott JH, Mattay VS et al: The Effect of Treatment with Antipsychotic Drugs on Brain N-Acetylaspartate Measures in Patients with Scizophrenia. Biol Psychiatry, 2001; 49: 39-46.
17. Szulc A, Galińska B, Tarasów E et al: Badania wybranych obszarów mózgu metoda spektroskopii protonowej rezonansu magnetycznego (1H MRS) w aspekcie dysfunkcji poznawczych i obrazu klinicznego u osób ze schizofrenia wczesna i przewlekła - doniesienie wstepne. Psychiatr Pol., in press.